



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/50945/2024

European Medicines Agency decision P/0049/2024

of 8 March 2024

on the granting of a product specific waiver for isatuximab (Sarclisa), (EMA-002205-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0049/2024

of 8 March 2024

on the granting of a product specific waiver for isatuximab (Sarclisa), (EMA-002205-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Sanofi Winthrop Industrie on 13 October 2023 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 January 2024 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

Article 1

A waiver for isatuximab (Sarclisa), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Sanofi Winthrop Industrie, 82 avenue Raspail, 94250 – Gentilly, France.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

EMA/PDCO/479313/2023
Amsterdam, 19 January 2024

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-002205-PIP02-23

Scope of the application

Active substance(s):

Isatuximab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Sanofi Winthrop Industrie

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Sanofi Winthrop Industrie submitted to the European Medicines Agency on 13 October 2023 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 20 November 2023.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

Authorised indication(s):

- SARCLISA is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy
 - Invented name(s): SARCLISA
 - Authorised pharmaceutical form(s): concentrate for solution for infusion
 - Authorised route(s) of administration: intravenous use
 - Authorised via centralised procedure
- SARCLISA is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
 - Invented name(s): SARCLISA
 - Authorised pharmaceutical form(s): concentrate for solution for infusion
 - Authorised route(s) of administration: intravenous use
 - Authorised via centralised procedure